Kaposi's sarcoma associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice

Cancer Biology and Therapy

Volumn 10, Issue 10, 2010, Pages 1033-1040

  Ahmad, Anwaar ^a   Groshong, Jason S ^a   Matta, Hittu ^a,b   Schamus, Sandra ^a   Punj, Vasu ^a,b   Robinson, Lisa J ^c   Gill, Parkash S ^b   Chaudhary, Preet M ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

K13; KSHV; Lymphoma; Myc; NF B; PEL; vFLIP

Indexed keywords

FLICE INHIBITORY PROTEIN; FLICE INHIBITORY PROTEIN K13; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG; MESSENGER RNA; MYC PROTEIN; VIRAL FLIP PROTEIN, HUMAN HERPESVIRUS 8; VIRUS PROTEIN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; HERPES VIRUS; HISTOPATHOLOGY; IMMUNOPHENOTYPING; KAPOSI SARCOMA; MOUSE; NONHUMAN; ONCOGENE C MYC; PATHOGENESIS; PRIMARY EFFUSION LYMPHOMA; ANIMAL; C57BL MOUSE; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; GENETICS; HUMAN HERPESVIRUS 8; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 8, HUMAN; IMMUNOENZYME TECHNIQUES; LYMPHOMA, PRIMARY EFFUSION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSFECTION; VIRAL PROTEINS;

EID: 78549291461     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.10.13291     Document Type: Article

References (54)

1. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007; 12:569-76.
2. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88:645-56.
3. Simonelli C, Spina M, Cinelli R, Talamini R, Tedeschi R, Gloghini A, et al. Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study. J Clin Oncol 2003; 21:3948-54.
4. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-9.
5. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-91.
6. + primary effusion lymphomas (body cavity-based lymphomas). Leukemia 1998; 12:1507-17.
7. Sturzl M, Hohenadl C, Zietz C, Castanos-Velez E, Wunderlich A, Ascherl G, et al. Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. J Natl Cancer Inst 1999; 91:1725-33. (Pubitemid 29518767)
8. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386:517-21.
9. Chaudhary PM, Jasmin A, Eby MT, Hood L. Modulation of the NFkappaB pathway by virally encoded death effector domains-containing proteins. Oncogene 1999; 18:5738-46.
10. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM. The Human Herpes Virus 8-encoded Viral FLICE Inhibitory Protein Physically Associates with and Persistently Activates the IkappaB Kinase Complex. J Biol Chem 2002; 277:13745-51.
11. Field N, Low W, Daniels M, Howell S, Daviet L, Boshoff C, et al. KSHV vFLIP binds to IKK-{gamma} to activate IKK. J Cell Sci 2003; 116:3721-8. (Pubitemid 37185301)
12. Matta H, Chaudhary PM. Activation of alternative NFkappaB pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci USA 2004; 101:9399-404.
13. Sun Q, Matta H, Chaudhary PM. The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NFkappaB activation. Blood 2003; 101:1956-61.
14. Sun Q, Zachariah S, Chaudhary PM. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NFkappaB activation. Journal of Biological Chemistry 2003; 278:52437-45. (Pubitemid 38035836)
15. Sun Q, Matta H, Lu G, Chaudhary PM. Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NFkappaB activation. Oncogene 2006; 25:2717-26.
16. Xu Y, Ganem D. Induction of chemokine production by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Gen Virol 2007; 88:46-50.
17. Grossmann C, Podgrabinska S, Skobe M, Ganem D. Activation of NFkappaB by the latent vFLIP gene of Kaposi's sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J Virol 2006; 80:7179-85.
18. Keller SA, Schattner EJ, Cesarman E. Inhibition of NFkappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000; 96:2537-42.
19. Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004; 199:993-1003. (Pubitemid 38481090)
20. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood 2005; 105:2510-8.
21. Zhao J, Punj V, Matta H, Mazzacurati L, Schamus S, Yang Y, et al. K13 Blocks KSHV Lytic Replication and Deregulates vIL6 and hIL6 Expression: a Model of Lytic Replication Induced Clonal Selection in Viral Oncogenesis. PLoS ONE 2007; 2:1067.
22. Chugh P, Matta H, Schamus S, Zachariah S, Kumar A, Richardson JA, et al. Constitutive NFkappaB activation, normal Fas-induced apoptosis and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc Natl Acad Sci USA 2005; 102:12885-90. (Pubitemid 41279459)
23. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2:764-76.
24. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982; 79:7824-7.
25. Rao PH, Houldsworth J, Dyomina K, Parsa NZ, Cigudosa JC, Louie DC, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998; 92:234-40. (Pubitemid 28303198)
26. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993; 5:56-61. (Pubitemid 23261519)
27. Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, Raffeld M. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene 1993; 8:2741-8.
28. Bubman D, Guasparri I, Cesarman E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 2007; 26:4979-86.
29. Liu J, Martin HJ, Liao G, Hayward SD. The Kaposi Sarcoma Associated Herpesvirus LANA Protein Stabilizes and Activates c-Myc. J Virol 2007.
30. Lubyova B, Kellum MJ, Frisancho JA, Pitha PM. Stimulation of c-Myc transcriptional activity by vIRF-3 of Kaposi sarcoma-associated herpesvirus. J Biol Chem 2007; 282:31944-53. (Pubitemid 350106417)
31. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, et al. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res 2005; 65:1306-15. (Pubitemid 40270157)
32. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6:203-8.
33. Karin M, Cao Y, Greten FR, Li ZW. NFkappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-10.
34. INK4A-induced cell cycle arrest. J Biol Chem 2005; 280:3862-74.
35. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194:1861-74.
36. Jost PJ, Ruland J. Aberrant NFkappaB signaling in lymphoma: mechanisms, consequences and therapeutic implications. Blood 2007; 109:2700-7. (Pubitemid 46482061)
37. Ratner L. Human T cell lymphotropic virus-associated leukemia/lymphoma. Curr Opin Oncol 2005; 17:469-73.
38. Evan G, Littlewood T. A matter of life and cell death. Science 1998; 281:1317-22.
39. Evan G, Harrington E, Fanidi A, Land H, Amati B, Bennett M. Integrated control of cell proliferation and cell death by the c-myc oncogene. Philos Trans R Soc Lond B Biol Sci 1994; 345:269-75.
40. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci 1998; 3:250-68.
41. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene 1999; 18:2967-87.
42. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348:331-3.
43. Strasser A, O'Connor L, Huang DC, O'Reilly LA, Stanley ML, Bath ML, et al. Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research. Behring Inst Mitt 1996; 101-17.
44. Cheung WC, Kim JS, Linden M, Peng L, Van Ness B, Polakiewicz RD, et al. Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice. J Clin Invest 2004; 113:1763-73.
45. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NFkappaB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia 2004; 18:11-7. (Pubitemid 38159433)
46. Karin M, Delhase M. The IkappaB kinase (IKK) and NFkappa B: key elements of proinflammatory signalling. Semin Immunol 2000; 12:85-98.
47. Karin M. Nuclear factor-[kappa]B in cancer development and progression. Nature 2006; 441:431.
48. Lee JS, Li Q, Lee JY, Lee SH, Jeong JH, Lee HR, et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol 2009.
49. Thurau M, Marquardt G, Gonin-Laurent N, Weinlander K, Naschberger E, Jochmann R, et al. Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death. J Virol 2009; 83:598-611.
50. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100:2961-9.
51. Bargou RC, Leng C, Krappmann D, Emmerich F, Mapara MY, Bommert K, et al. High-level nuclear NFkappaB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996; 87:4340-7. (Pubitemid 26155031)
52. Packham G. The role of NFkappaB in lymphoid malignancies. Br J Haematol 2008; 143:3-15.
53. Rui L, Goodnow CC. Lymphoma and the control of B cell growth and differentiation. Curr Mol Med 2006; 6:291-308.
54. Lu G, Punj V, Chaudhary PM. Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL. Cancer Biol Ther 2008; 7:603-8.